Surgical treatment for pancreatic neuroendocrine neoplasmas.
- Author:
Junli WU
1
;
Feng GUO
1
;
Jishu WEI
1
;
Zipeng LU
1
;
Jianmin CHEN
1
;
Wentao GAO
1
;
Qiang LI
1
;
Kuirong JIANG
1
;
Cuncai DAI
1
;
Yi MIAO
1
Author Information
1. Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Lymph Node Excision;
Neoplasm Metastasis;
Neuroendocrine Tumors;
surgery;
Pancreatectomy;
Pancreatic Neoplasms;
surgery
- From:
Journal of Zhejiang University. Medical sciences
2016;45(1):31-35
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic neuroendocrine neoplasmas (PNENs) are classified into functioning & non-functioning tumors. The radical surgery is the only effective way for the cure & long-term survival. For the locoregional resectable tumors, the surgical resection is the first choice of treatment; the surgical procedures include local resection (enucleation) and standard resection. For the insulinomas and non-functioning tumors less than 2 cm, local resection (enucleation),distal pancreatectomy with spleen-preservation or segmental pancreatectomy are the commonly selected procedures. The radical resections with regional lymph nodes dissection, including pancreaticoduodenectomy, distal pancreatectomy and middle segmental pancreatectomy, should be applied for tumors more than 2 cm or malignant ones. For the locoregional advanced or unresectable functioning tumors, debulking surgery should be performed and more than 90% of the lesions including primary and metastatic tumors should be removed; for the non-functioning tumors, if complicated with biliary & digestive tract obstruction or hemorrhage, the primary tumors should be resected. The liver is the most frequent site of metastases for PNENs and three types of metastases are defined. For typeⅠmetastasis, patients are recommended for surgery if there are no contraindications; For type II metastasis, debulking surgery should be applied and at least 90% of metastatic lesions should be resected, and for patients with primary tumors removed and no extrahepatic metastases, or for patients with well-differentiated (G1/G2) tumors, liver transplantation may be indicated. For the unresectable type Ⅲ metastasis, multiple adjuvant therapies should be chosen.
